Claims for Patent: 6,127,173

Summary for Patent: 6,127,173

Title:	Nucleic acid catalysts with endonuclease activity
Abstract:	Nucleic acid molecules with new motifs having catalytic activity, methods of synthesis, and use thereof are also described.
Inventor(s):	Eckstein; Fritz (Gottingen, DE), Heaton; Paul A. (Warrington, GB), Vaish; Narendra K. (Brighton, MA)
Assignee:	Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:	09/159,274
Patent Claims:	1. A nucleic acid molecule with an endonuclease activity having the formula I: ##STR2## wherein, each N represents independently a nucleotide or an abasic moiety, which may be same or different; X and Y are independent oligonucleotides of length sufficient to stably interact with a target nucleic acid molecule; m and n are integers greater than or equal to 1, wherein if (N).sub.m and (N).sub.n are nucleotides, (N)m and (N)n may interact by hydrogen bond interaction; J is an oligonucleotide having a sequence selected from the group consisting of 5'-GGCAUCC-3', 5'-AGCAUU-3', 5'-GCAUCA-3', 5'-AGCAUC-3', and, 5'-AGCGUC-3'; L is a linker which may be present or absent, wherein said linker, when present, is a nucleotide linker or a non-nucleotide linker, or a combination of nucleotide and a non-nucleotide linker, wherein said nucleotide linker comprises a single-stranded region, or double-stranded region, or a combination of single-stranded and a double-stranded region; represents a chemical linkage; and C and G represent cytidine and guanosine nucleotides, respectively. 2. A nucleic acid molecule with an endonuclease activity having the formula II: ##STR3## wherein, each N represents independently a nucleotide or a non-nucleotide linker, which may be same or different; X and Y are independent oligonucleotides of length sufficient to stably interact with a target nucleic acid molecule; m and n are integers greater than or equal to 1, wherein if (N).sub.m and (N).sub.n are nucleotides, (N)m and (N)n may interact by hydrogen bond interaction; J is an oligonucleotide of length 6 nucleotides having a sequence 5'-GGAAUC-3'; L is a linker which may be present or absent, wherein said linker, when present, is a nucleotide linker or a non-nucleotide linker, or a combination of nucleotide and a non-nucleotide linker, wherein said nucleotide linker comprises a single-stranded region, or double-stranded region, or a combination of single-stranded and a double-stranded region; represents a chemical linkage; and C represents cytidine nucleotide. 3. A nucleic acid molecule with endonuclease activity having the formula III: ##STR4## wherein, each N represents independently a nucleotide or a non-nucleotide linker, which may be same or different; X and Y are independent oligonucleotides of length sufficient to stably interact with a target nucleic acid molecule; m and n are integers greater than or equal to 1, wherein if (N).sub.m and (N).sub.n are nucleotides, (N)m and (N)n may interact by hydrogen bond interaction; K is an oligonucleotide of length 5 nucleotides having a sequence selected from the group consisting of 5'-UGAUG-3', 5'-UGAUC-3', and 5'-UGGGC-3'; L is a linker which may be present or absent, wherein said linker, when present, is a nucleotide linker or a non-nucleotide linker, or a combination of nucleotide and a non-nucleotide linker, wherein said nucleotide linker comprises a single-stranded region, or double-stranded region, or a combination of single-stranded and a double-stranded region; represents a chemical linkage; and C and G represent cytidine and guanosine nucleotides, respectively. 4. The nucleic acid molecules of any of claims 1-3, wherein said L in said nucleic acid molecule is nucleotide linker. 5. The nucleic acid molecule of claim 4, wherein said nucleotide linker is a nucleic acid aptamer. 6. The nucleic acid molecule of claim 5, wherein said aptamer is an ATP aptamer. 7. The nucleic acid molecule of any of claims 1-3, wherein said L is non-nucleotide linker. 8. The nucleic acid molecule of any of claims 1-3, wherein said (N)m and (N)n each have a nucleotide sequence. 9. The nucleic acid molecule of claim 8, wherein said nucleotide sequence of said (N)m is complementary to the nucleotide sequence of said (N)n. 10. The nucleic acid molecule of any of claims 1-3, wherein said nucleic acid cleaves a separate nucleic acid molecule. 11. The nucleic acid molecule of claim 10, wherein said separate nucleic acid molecule is RNA. 12. The nucleic acid molecule of claim 10, wherein said nucleic acid comprises between 12 and 100 bases complementary to said separate nucleic acid molecule. 13. The nucleic acid molecule of claim 10, wherein said nucleic acid comprises between 14 and 24 bases complementary to said separate nucleic acid molecule. 14. A cell including the nucleic acid molecule of any of claims 1-3, wherein said cell is not a living human. 15. The cell of claim 14, wherein said cell is a mammalian cell. 16. The cell of claim 15, wherein said cell is a human cell. 17. An expression vector comprising nucleic acid sequence encoding at least one of the nucleic acid molecule of any of claims 1-3, in a manner which allows expression of that nucleic acid molecule. 18. A cell including the expression vector of claim 17, wherein said cell is not a living human. 19. The cell of claim 18, wherein said cell is a mammalian cell. 20. The cell of claim 18, wherein said cell is a human cell. 21. A method of cleaving a separate nucleic acid comprising, contacting the nucleic acid molecule of any of claims 1-3 with said separate nucleic acid molecule under conditions suitable for the cleavage of said separate nucleic acid molecule. 22. The method of claim 21, wherein said cleavage is carried out in the presence of a divalent cation. 23. The method of claim 22, wherein said divalent cation is Mg.sup.2+. 24. The nucleic acid molecule of claims 1-3, wherein said nucleic acid is chemically synthesized. 25. The expression vector of claim 17, wherein said vector comprises: a) a transcription initiation region; b) a transcription termination region; c) a gene encoding at least one said nucleic acid molecule; and wherein said gene is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. 26. The expression vector of claim 17, wherein said vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an open reading frame; d) a gene encoding at least one said nucleic acid molecule, wherein said gene is operably linked to the 3'-end of said open reading frame; and wherein said gene is operably linked to said initiation region, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. 27. The expression vector of claim 17, wherein said vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) a gene encoding at least one said nucleic acid molecule; and wherein said gene is operably linked to said initiation region, said intron and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. 28. The expression vector of claim 17, wherein said vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) an open reading frame; e) a gene encoding at least one said nucleic acid molecule, wherein said gene is operably linked to the 3'-end of said open reading frame; and wherein said gene is operably linked to said initiation region, said intron, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.

Details for Patent 6,127,173

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	June 04, 1986		2018-09-22
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132			2018-09-22
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	Injection	103132			2018-09-22